Regeneron (REGN) and Relief Therapeutics (OTC:RLFTF) can quickly reduce COVID-19

Together, Relief Therapeutics (OTC:RLFTF) and Regeneron (REGN) can quickly reduce COVID-19. U.S. officials has officially granted Regeneron emergency use authorization for it’s experimental antibody treatment that was given to Trump after his COVID diagnosis.

The drug, developed by Regeneron, will be allowed for use in people who have tested positive for the virus and are at risk of severe illness.

Studies suggest the therapy is effective when administered early after diagnosis, the company says.

It comes as Covid-19 cases in the country continue to rise.

Emergency authorization by the Food and Drug Administration (FDA) allows use of a treatment while studies are carried out to determine safety and effectiveness.

A similar drug made by Eli Lilly (LLY), another US pharmaceutical firm, was given emergency approval earlier this month.

The Regeneron treatment is a combination of two monoclonal antibodies – potent, laboratory-made antibodies – which mimic our own immune response. They physically stick to the coronavirus so they cannot get inside the body’s cells.

Regeneron said it expected to have enough doses for about 80,000 patients by the end of this month and 300,000 in total by the end of January. The treatment will be provided for free but patients may have to pay for having it administered.

The FDA said the treatment was not authorized for Covid patients who are in hospital or require oxygen.

The drug was one of a number President Trump received after testing positive for Covid-19 in October. The president later credited the experimental therapy for aiding his recovery – though it remains impossible to know whether it did.

President Trump was one of only a handful of people outside clinical trials to be given the drug, under what is known as “compassionate use”.

Regeneron (REGN) & Relief Therapeutics (OTC:RLFTF) a powerful combo

Regeneron’s drug is for early use

Unlike some other drugs used for Covid-19, the antibody cocktail is meant to be given early in infection, before patients are hospitalized or require oxygen therapy. The drug should be given as soon as possible after a positive viral test, according to the FDA.

The FDA’s authorization is limited to high-risk patients, like those who are older than 65 years of age or have a BMI greater than or equal to 35. Patients with other conditions like diabetes, cardiovascular disease or chronic kidney disease also qualify for the drug.

The authorization only applies to patients 12 years of age or older. The cocktail has not been authorized for use in patients who are hospitalized with Covid-19 or need oxygen therapy because of Covid-19.

Relief Therapeutics’ drug is for moderate & severely ill patients

RLF-100 is used for patients who are hospitalized and has exhausted every other possible treatment that could in other words work as intended.

Beyond COVID-19, Relief’s objective is to establish RLF-100™ as the standard of care for Intensive Care Units (ICUs) in acute as well as chronic contexts to prevent and cure respiratory failure and its complications.

Where to put $15 right now

STOP BUYING STOCKS RIGHT NOW … And start taking a serious look at options, the investment vehicle that is driving stocks like Tesla and Apple to historically unprecedented highs.

Subscribe below to get insight into options trades!

Jay Lorrence
Jay Lorrence

Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.

Articles: 233

Newsletter Updates

Enter your email address below to subscribe to our newsletter